or Try an Advanced Search...

    Histone Deacetylase Inhibitor Stocks List

    Symbol Grade Name % Change
    MEIP D MEI Pharma, Inc. 1.75
    SNDX F Syndax Pharmaceuticals, Inc. -2.38
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Cancer Clinical Medicine Medicine Solid Tumors Antineoplastic Drugs Benzamides Breast Cancer Cancer Cell Cancer Therapies Clinical Development Hematological Malignancies Lung Cancer National Cancer Institute Novogen Pyridines Refractory Solid Tumors Treatment Of Breast Cancer Treatment Of Cancer Virotherapy

    Related ETFs - A few ETFs which own one or more of the above listed Histone Deacetylase Inhibitor stocks.

    Symbol Grade Name Weight
    SURI C Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 1.47
    CNCR F Loncar Cancer Immunotherapy ETF 1.34
    SBIO C ALPS Medical Breakthroughs ETF 0.93
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.66
    XBI D SPDR S&P Biotech ETF 0.44
    View all Histone Deacetylase Inhibitor ETFs...
    Compare ETFs
    Compare CNCR to SBIO Compare SURI to BBC Compare SURI to XBI

        Histone Deacetylase Inhibitor Stocks Recent News

        Date Stock Title
        Nov 18 SNDX Syndax secures FDA OK for new kind of leukemia drug
        Nov 18 SNDX FDA approves Syndax’s Revuforj to treat leukaemia
        Nov 17 MEIP Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
        Nov 15 SNDX Syndax wins FDA approval for leukemia drug revumenib
        Nov 15 SNDX Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Cancer Clinical Medicine Medicine Solid Tumors Antineoplastic Drugs Benzamides Breast Cancer Cancer Cell Cancer Therapies Clinical Development Hematological Malignancies Lung Cancer National Cancer Institute Novogen Pyridines Refractory Solid Tumors Treatment Of Breast Cancer Treatment Of Cancer Virotherapy
        Histone Deacetylase Inhibitor

        Histone deacetylase inhibitors (HDAC inhibitors) are a class of drugs that inhibit the activity of histone deacetylases, enzymes that modify the structure of chromatin by removing acetyl groups from histones. HDAC inhibitors are used to treat a variety of diseases, including cancer, and have been studied as potential treatments for neurodegenerative diseases.

        Browse All Tags